PharmiWeb Today Story
- Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had no standard of care
- In TRANSCEND CLL 004, the first pivotal multicenter trial to evaluate a CAR T cell therapy in patients with relapsed or refractory CLL or SLL, 20% of patients treated with Breyanzi achieved a complete response (CR) with median duration of CR not reached, along with an established safety profile
- Breyanzi is now FDA approved for relapsed or refractory large B-cell lymphoma and CLL or SLL, bringing this differentiated CD19-directed CAR T cell therapy to more patients
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). In R/R CLL or SLL, Breyanzi is delivered…
Read More...Articles
Average UK Clinical Research Salaries in 2024
07-Mar-2024
Top 9 Clinical Research Organisations in 2024
06-Mar-2024
5 Clinical Research Recruitment Trends for 2024
05-Mar-2024
What is Life Science?
21-Feb-2024
Featured Events
-
Reuters Events: Cell & Gene Therapy USA 2021
28-Sep-2021 - 29-Sep-2021 -
Reuters Events: Pharma 2021
11-Oct-2021 - 22-Oct-2021 -
Pharmaceutical Manufacturing and Packaging Congres…
20-Jun-2022 - 21-Jun-2022 -
AI in Healthcare Summit Boston 2022
13-Oct-2022 - 14-Oct-2022 -
How to impact, influence & inspire
07-Feb-2023 - 21-Feb-2023 -
Finding the Value in Strategic Outsourcing Partner…
22-Feb-2023 - 22-Feb-2023
News
-
Medical Transcription Outsourcing Service Market i…
19-Mar-2024 -
IRLAB’s Mesdopetam Displays Antipsychotic Properti…
19-Mar-2024 -
Newron presents 2023 financial results and provide…
19-Mar-2024 -
PolyPeptide publishes invitation to the annual Gen…
19-Mar-2024 -
Dental Nano Ceramic Block Market: Exploring the Fu…
19-Mar-2024 -
Forensic Light System Market – A Comprehensive Ana…
19-Mar-2024